magnolol has been researched along with Neointima in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karki, R; Kim, DW; Kim, SB | 1 |
| Ho, OM; Karki, R; Kim, DW | 1 |
2 other study(ies) available for magnolol and Neointima
| Article | Year |
|---|---|
Magnolol inhibits migration of vascular smooth muscle cells via cytoskeletal remodeling pathway to attenuate neointima formation.
Topics: Animals; Biphenyl Compounds; Carotid Arteries; Cell Adhesion; Cell Movement; Cells, Cultured; Cytoskeleton; Dose-Response Relationship, Drug; Lignans; Magnolia; Muscle, Smooth, Vascular; Neointima; Rats; Structure-Activity Relationship | 2013 |
Magnolol attenuates neointima formation by inducing cell cycle arrest via inhibition of ERK1/2 and NF-kappaB activation in vascular smooth muscle cells.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; Carotid Arteries; Carotid Artery Injuries; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Lignans; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha | 2013 |